Sign Out
Hypersensitivity to empagliflozin or linagliptin or any of the excipients.
Patients with severe renal impairment (eGFR <30 mL/min/1.73 m2), end-stage renal disease and patients on dialysis. The efficacy of empagliflozin is dependent on renal function (see Precautions).
